gshj480

Property	Value
?:abstract	OBJECTIVE: To investigate the effectiveness of using convalescent plasma to treat moderate coronavirus disease 2019 (covid-19) in adults in India. DESIGN: Open label, parallel arm, phase II, multicentre, randomised controlled trial. SETTING: 39 public and private hospitals across India. PARTICIPANTS: 464 adults (≥18 years) admitted to hospital (screened 22 April to 14 July 2020) with confirmed moderate covid-19 (partial pressure of oxygen in arterial blood/fraction of inspired oxygen (PaO(2)/FiO(2)) ratio between 200 mm Hg and 300 mm Hg or a respiratory rate of more than 24/min with oxygen saturation 93% or less on room air): 235 were assigned to convalescent plasma with best standard of care (intervention arm) and 229 to best standard of care only (control arm). INTERVENTIONS: Participants in the intervention arm received two doses of 200 mL convalescent plasma, transfused 24 hours apart. The presence and levels of neutralising antibodies were not measured a priori; stored samples were assayed at the end of the study. MAIN OUTCOME MEASURE: Composite of progression to severe disease (PaO(2)/FiO(2) <100 mm Hg) or all cause mortality at 28 days post-enrolment. RESULTS: Progression to severe disease or all cause mortality at 28 days after enrolment occurred in 44 (19%) participants in the intervention arm and 41 (18%) in the control arm (risk difference 0.008 (95% confidence interval −0.062 to 0.078); risk ratio 1.04, 95% confidence interval 0.71 to 1.54). CONCLUSION: Convalescent plasma was not associated with a reduction in progression to severe covid-19 or all cause mortality. This trial has high generalisability and approximates convalescent plasma use in real life settings with limited laboratory capacity. A priori measurement of neutralising antibody titres in donors and participants might further clarify the role of convalescent plasma in the management of covid-19. TRIAL REGISTRATION: Clinical Trial Registry of India CTRI/2020/04/024775.
is ?:annotates of	<https://research.tib.eu/covid-19/entity/5gshj480_hasAnnotation_C1314715> <https://research.tib.eu/covid-19/entity/5gshj480_hasAnnotation_C3715044>
?:creator	<https://research.tib.eu/covid-19/entity/Agarwal%2C_Anup%3B_Mukherjee%2C_Aparna%3B_Kumar%2C_Gunjan%3B_Chatterjee%2C_Pranab%3B_Bhatnagar%2C_Tarun%3B_Malhotra%2C_Pankaj%3B_Agarwal%2C_Anup%3B_Mukherjee%2C_Aparna%3B_Kumar%2C_Gunjan%3B_Chatterjee%2C_Pranab%3B_Bhatnagar%2C_Tarun%3B_Malhotra%2C_Pankaj%3B_Latha%2C_B%3B_Bundas%2C_Sunita%3B_Kumar%2C_Vivek%3B_Dosi%2C_Ravi%3B_Khambholja%2C_Janak_Kumar%3B_de_Souza%2C_Rosemarie%3B_Mesipogu%2C_Raja_Rao%3B_Srivastava%2C_Saurabh%3B_Dube%2C_Simmi%3B_Chaudhary%2C_Kiran%3B_Subash%2C_S%3B_Anbuselvi%2C_S%3B_Rajendran%2C_V%3B_Sundararajaperumal%2C_A%3B_Balamanikandan%2C_P%3B_Maheswari%2C_R_S_Uma%3B_Jayanthi%2C_R%3B_Ragunanthanan%2C_S%3B_Bhandari%2C_Sudhir%3B_Singh%2C_Ajeet%3B_Pal%2C_Ashok%3B_Handa%2C_Anjali%3B_Rankawat%2C_Govind%3B_Kargirwar%2C_Ketan%3B_Regi%2C_Joyce%3B_Rathod%2C_Darshana%3B_Pathrose%2C_Edwin%3B_Bhutaka%2C_Nirankar%3B_Patel%2C_Mayur_H%3B_Verma%2C_Rahul_J%3B_Malukani%2C_Kamal%3B_Patel%2C_Shivani%3B_Thakur%2C_Apurv%3B_Joshi%2C_Satish%3B_Kulkarni%2C_Rashmi%3B_Suthar%2C_Nilay_N%3B_Shah%2C_Nehal_M%3B_Purohit%2C_Hemang_M%3B_Shah%2C_Cherry_K%3B_Patel%2C_Monila_N%3B_Shah%2C_Saket%3B_Shah%2C_Smit_T%3B_Memon%2C_Tehsim%3B_Beriwala%2C_Vishal_R%3B_Jashnani%2C_Kusum%3B_Ezzy%2C_Fatema%3B_Agrawal%2C_Simran%3B_Bhadade%2C_Rakesh%3B_Atish%2C_MN%3B_Madke%2C_Tushar%3B_Kavishwar%2C_Vikas%3B_Waghmare%2C_Ramesh%3B_Valvi%2C_Nitin%3B_Chander%2C_B_Thrilok%3B_Sekhar%2C_A_Vinaya%3B_Maurya%2C_Akhilesh_Kumar%3B_Hemanth%2C_K%3B_Nagamani%2C_K%3B_Sudha%2C_K%3B_Chandra%2C_T_Ravi%3B_Rao%2C_K_Tushara%3B_Vyshnavi%2C_J%3B_Upadhyay%2C_Rashmi%3B_Bahadur%2C_Shalini%3B_Pathak%2C_Rambha%3B_Seth%2C_Shikha%3B_Gupta%2C_Rakesh%3B_Saxena%2C_Rita%3B_Dwivedi%2C_Preksha%3B_Malik%2C_Reeni%3B_Chourasia%2C_Deepti%3B_Lalwani%2C_Jaya%3B_Sharma%2C_UM%3B_Marko%2C_JL%3B_Suri%2C_Amit%3B_Kumar%2C_Vijay%3B_Kaushik%2C_Rajnish%3B_Kodan%2a79f7026a84064d2f27f28d59655c225>
?:doi	<https://research.tib.eu/covid-19/entity/10.1136/bmj.m3939>
?:doi	10.1136/bmj.m3939
?:journal	BMJ
?:license	cc-by-nc
?:pdf_json_files	document_parses/pdf_json/ce88a972dfdbe10759416c207c475d5b1650bb31.json
?:pmc_json_files	document_parses/pmc_json/PMC7578662.xml.json
?:pmcid	<https://research.tib.eu/covid-19/entity/PMC7578662>
?:pmid	<https://research.tib.eu/covid-19/entity/33093056.0>
?:pmid	33093056.0
?:publication_isRelatedTo_Disease	<https://research.tib.eu/covid-19/entity/COVID-19>
?:sha_id	<https://research.tib.eu/covid-19/entity/ce88a972dfdbe10759416c207c475d5b1650bb31>
?:source	Medline; PMC
?:title	Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial)
?:type	<https://research.tib.eu/covid-19/vocab/Publication>
?:year	2020-10-23

Property

Value

?:abstract

OBJECTIVE: To investigate the effectiveness of using convalescent plasma to treat moderate coronavirus disease 2019 (covid-19) in adults in India. DESIGN: Open label, parallel arm, phase II, multicentre, randomised controlled trial. SETTING: 39 public and private hospitals across India. PARTICIPANTS: 464 adults (≥18 years) admitted to hospital (screened 22 April to 14 July 2020) with confirmed moderate covid-19 (partial pressure of oxygen in arterial blood/fraction of inspired oxygen (PaO(2)/FiO(2)) ratio between 200 mm Hg and 300 mm Hg or a respiratory rate of more than 24/min with oxygen saturation 93% or less on room air): 235 were assigned to convalescent plasma with best standard of care (intervention arm) and 229 to best standard of care only (control arm). INTERVENTIONS: Participants in the intervention arm received two doses of 200 mL convalescent plasma, transfused 24 hours apart. The presence and levels of neutralising antibodies were not measured a priori; stored samples were assayed at the end of the study. MAIN OUTCOME MEASURE: Composite of progression to severe disease (PaO(2)/FiO(2) <100 mm Hg) or all cause mortality at 28 days post-enrolment. RESULTS: Progression to severe disease or all cause mortality at 28 days after enrolment occurred in 44 (19%) participants in the intervention arm and 41 (18%) in the control arm (risk difference 0.008 (95% confidence interval −0.062 to 0.078); risk ratio 1.04, 95% confidence interval 0.71 to 1.54). CONCLUSION: Convalescent plasma was not associated with a reduction in progression to severe covid-19 or all cause mortality. This trial has high generalisability and approximates convalescent plasma use in real life settings with limited laboratory capacity. A priori measurement of neutralising antibody titres in donors and participants might further clarify the role of convalescent plasma in the management of covid-19. TRIAL REGISTRATION: Clinical Trial Registry of India CTRI/2020/04/024775.

is ?:annotates of

?:creator

<https://research.tib.eu/covid-19/entity/Agarwal%2C_Anup%3B_Mukherjee%2C_Aparna%3B_Kumar%2C_Gunjan%3B_Chatterjee%2C_Pranab%3B_Bhatnagar%2C_Tarun%3B_Malhotra%2C_Pankaj%3B_Agarwal%2C_Anup%3B_Mukherjee%2C_Aparna%3B_Kumar%2C_Gunjan%3B_Chatterjee%2C_Pranab%3B_Bhatnagar%2C_Tarun%3B_Malhotra%2C_Pankaj%3B_Latha%2C_B%3B_Bundas%2C_Sunita%3B_Kumar%2C_Vivek%3B_Dosi%2C_Ravi%3B_Khambholja%2C_Janak_Kumar%3B_de_Souza%2C_Rosemarie%3B_Mesipogu%2C_Raja_Rao%3B_Srivastava%2C_Saurabh%3B_Dube%2C_Simmi%3B_Chaudhary%2C_Kiran%3B_Subash%2C_S%3B_Anbuselvi%2C_S%3B_Rajendran%2C_V%3B_Sundararajaperumal%2C_A%3B_Balamanikandan%2C_P%3B_Maheswari%2C_R_S_Uma%3B_Jayanthi%2C_R%3B_Ragunanthanan%2C_S%3B_Bhandari%2C_Sudhir%3B_Singh%2C_Ajeet%3B_Pal%2C_Ashok%3B_Handa%2C_Anjali%3B_Rankawat%2C_Govind%3B_Kargirwar%2C_Ketan%3B_Regi%2C_Joyce%3B_Rathod%2C_Darshana%3B_Pathrose%2C_Edwin%3B_Bhutaka%2C_Nirankar%3B_Patel%2C_Mayur_H%3B_Verma%2C_Rahul_J%3B_Malukani%2C_Kamal%3B_Patel%2C_Shivani%3B_Thakur%2C_Apurv%3B_Joshi%2C_Satish%3B_Kulkarni%2C_Rashmi%3B_Suthar%2C_Nilay_N%3B_Shah%2C_Nehal_M%3B_Purohit%2C_Hemang_M%3B_Shah%2C_Cherry_K%3B_Patel%2C_Monila_N%3B_Shah%2C_Saket%3B_Shah%2C_Smit_T%3B_Memon%2C_Tehsim%3B_Beriwala%2C_Vishal_R%3B_Jashnani%2C_Kusum%3B_Ezzy%2C_Fatema%3B_Agrawal%2C_Simran%3B_Bhadade%2C_Rakesh%3B_Atish%2C_MN%3B_Madke%2C_Tushar%3B_Kavishwar%2C_Vikas%3B_Waghmare%2C_Ramesh%3B_Valvi%2C_Nitin%3B_Chander%2C_B_Thrilok%3B_Sekhar%2C_A_Vinaya%3B_Maurya%2C_Akhilesh_Kumar%3B_Hemanth%2C_K%3B_Nagamani%2C_K%3B_Sudha%2C_K%3B_Chandra%2C_T_Ravi%3B_Rao%2C_K_Tushara%3B_Vyshnavi%2C_J%3B_Upadhyay%2C_Rashmi%3B_Bahadur%2C_Shalini%3B_Pathak%2C_Rambha%3B_Seth%2C_Shikha%3B_Gupta%2C_Rakesh%3B_Saxena%2C_Rita%3B_Dwivedi%2C_Preksha%3B_Malik%2C_Reeni%3B_Chourasia%2C_Deepti%3B_Lalwani%2C_Jaya%3B_Sharma%2C_UM%3B_Marko%2C_JL%3B_Suri%2C_Amit%3B_Kumar%2C_Vijay%3B_Kaushik%2C_Rajnish%3B_Kodan%2a79f7026a84064d2f27f28d59655c225>

?:doi

<https://research.tib.eu/covid-19/entity/10.1136/bmj.m3939>

?:doi

10.1136/bmj.m3939

?:journal

?:license

cc-by-nc

?:pdf_json_files

document_parses/pdf_json/ce88a972dfdbe10759416c207c475d5b1650bb31.json

?:pmc_json_files

document_parses/pmc_json/PMC7578662.xml.json

?:pmcid

<https://research.tib.eu/covid-19/entity/PMC7578662>

?:pmid

<https://research.tib.eu/covid-19/entity/33093056.0>

?:pmid

33093056.0

?:publication_isRelatedTo_Disease

<https://research.tib.eu/covid-19/entity/COVID-19>

?:sha_id

<https://research.tib.eu/covid-19/entity/ce88a972dfdbe10759416c207c475d5b1650bb31>

?:source

Medline; PMC

?:title

Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial)

?:type

<https://research.tib.eu/covid-19/vocab/Publication>

?:year

2020-10-23

Anon_0

<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>

<http://purl.org/net/provenance/ns#DataItem>

<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>

<http://www.w3.org/2004/03/trix/rdfg-1/Graph>

<http://xmlns.com/foaf/0.1/primaryTopic>

<https://research.tib.eu/covid-19/entity/5gshj480>

<http://xmlns.com/foaf/0.1/topic>

Anon_0

<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes>

<https://research.tib.eu/covid-19/data/entity/5gshj480>

<http://purl.org/net/provenance/ns#createdBy>

Anon_1 (more)

Metadata